Study offers promising new drug therapy for premature aging disease

A drug originally developed to treat cancer could help children with progeria, a rare genetic disorder, to live longer.


A new study by the scientists from the Brown University recommends that a test tranquilize treatment can expand the lives of youngsters with progeria, an uncommon hereditary issue that causes untimely maturing and passing.

The examination demonstrated that youngsters with progeria who were treated with lonafarnib, a medication initially created to treat growth, will probably get by finishing the course the investigation contrasted and kids with progeria who did not get the medication. The investigation is preparatory, yet the analysts say the outcomes propose a promising road for treating a condition for which there are as of now no endorsed treatments.

Progeria, a Hutchinson-Gilford Progeria syndrome caused due to gene mutations- whose protein item keeps up ordinary structure and capacity in the cell core. It’s suspected that the sickness causing protein progerin causes flimsiness in cores all through the body and prompts a fast maturing process.

Children with progeria seem progressed in age and experience age-related conditions like male pattern baldness, joint agony, and cardiovascular ailment. Kids with the condition experience a normal of 14.5 years and bite the dust because of fast movement of atherosclerosis.

Dr. Leslie Gordon, lead author of the study said, “This study provides supporting evidence that we can begin to put the brakes on the rapid aging process for children with progeria. These results provide new promise and optimism to the progeria community.”

The examination occurred at Boston Children’s Hospital, Brown University, and Hasbro youngsters’ Hospital. Specialists took after 27 youngsters with progeria who had taken twice-every day dosages of lonafarnib in a clinical trial at Boston Children’s Hospital.

The examination amass was contrasted with a gathering of 27 offspring of comparable age who had progeria, however, were not some portion of the trial and did not get the medication. The examination demonstrated an essentially bring down death rate in the gathering getting lonafarnib treatment. Following two years, mortality in the treatment gather was 3.7 percent, contrasted with 33.3 percent in the untreated gathering.

It’s uncertain from the examination precisely what the medication is doing that may expand youngsters’ lives. But since most youngsters with progeria kick the bucket of coronary illness and strokes, “the lower death rate may have been inferable from cardiovascular and potentially cerebrovascular advantage.”

Dr. Francis Collins, director of the National Institutes of Health, led the lab that first identified the mutation that causes progeria.

“My lab did some of the original research on cellular and mouse models that showed the potential benefit of this class of drugs for Progeria,” said Collins, who was not involved in the new study. “It was encouraging to see those results translated into a clinical trial. Yet demonstrating the effectiveness of treatments in this small population of children with this rare fatal disease is a major challenge. Thus, I’m particularly encouraged by these latest findings.”

Gordon, the study’s lead author, is the medical director of The Progeria Research Foundation, which funded the research. She and her husband, Dr. Scott Berns, co-founded the nonprofit organization in 1999 after the couple’s son, Sam, was diagnosed.

A study is published today in the Journal of the American Medical Association.

Latest Updates